Valuation : DMS

Market Cap 2.62Cr 3.04Cr 2.45Cr 2.24Cr 4.22Cr 290.31Cr 4.23Cr 29Cr 11Cr 146.55Cr 11Cr 11Cr 485.92Cr P/E 2026 *
33.7x
P/E 2027 * 10.1x
Enterprise Value 4.16Cr 4.82Cr 3.9Cr 3.56Cr 6.7Cr 461.12Cr 6.72Cr 46Cr 18Cr 232.77Cr 18Cr 18Cr 771.82Cr EV / Sales 2026 *
0.73x
EV / Sales 2027 * 0.52x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.05Cr
+0.27%-4.03%-22.15%+1.11% 1.28TCr
-3.83%-4.39%+15.64%+7.50% 458.55Cr
-0.20%-5.70%-40.72%-54.95% 123.64Cr
+1.00%-3.99%-37.47%-35.66% 114.75Cr
+0.66%-0.43%+19.79%+87.54% 111.25Cr
-1.14%-8.57%-38.84% - 105.98Cr
+0.95%-4.24%+37.21%+123.00% 53Cr
-1.07%-0.17%+52.93% - 30Cr
+2.21%-6.70%-66.05%+301.00% 24Cr
Average -0.12%-0.14%-8.85%+61.36% 255.78Cr
Weighted average by Cap. -0.56%-0.13%-13.22%+8.07%

Financials

2026 *2027 *
Net sales 5.68Cr 6.59Cr 5.33Cr 4.86Cr 9.16Cr 629.99Cr 9.19Cr 63Cr 25Cr 318.01Cr 25Cr 24Cr 1.05TCr 6.59Cr 7.65Cr 6.18Cr 5.64Cr 11Cr 730.92Cr 11Cr 73Cr 29Cr 368.96Cr 29Cr 28Cr 1.22TCr
Net income 8L 9L 8L 7L 12.9L 8.87Cr 12.94L 88.99L 34.72L 4.48Cr 34.86L 34.1L 15Cr 26L 30.17L 24.38L 22.25L 41.92L 29Cr 42.06L 2.89Cr 1.13Cr 15Cr 1.13Cr 1.11Cr 48Cr
Net Debt 1.54Cr 1.79Cr 1.44Cr 1.32Cr 2.48Cr 170.81Cr 2.49Cr 17Cr 6.68Cr 86Cr 6.71Cr 6.56Cr 285.9Cr 80L 92.84L 75.01L 68.47L 1.29Cr 89Cr 1.29Cr 8.9Cr 3.47Cr 45Cr 3.49Cr 3.41Cr 148.52Cr
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-